Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners

Photo of Alex Sirois
By Alex Sirois Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners

© iip-photo-archive / Flickr

President Trump’s 12-word remark, “I don’t think about Americans’ financial situation, I don’t think about anybody,” hit the wires, and the reaction showed up in the forgotten corners of the market, where micro-cap turnarounds priced like option contracts ripped higher on May 15 as traders rotated into beaten-down names with operational catalysts already in motion. When the headline tape gets emotional, sub-$30 stocks with a real story attached tend to move first and hardest.

With that in mind, here are three stocks trading under $30 that surged on May 15, 2026, and where the underlying fundamentals support the move rather than just the headline.

P3 Health Partners (NASDAQ: PIII)

P3 Health Partners (NASDAQ:PIII) is a value-based care operator serving Medicare Advantage populations. Shares closed at $11.29 on May 15, up roughly 180% on the day on volume of 64.2 million shares. For a retail investor, that is a name that just announced itself.

The Q1 2026 report filed May 14, 2026 showed EPS of $0.32 versus a consensus of -$3.50, revenue of $386.39 million (+3.5% YoY), and a swing to GAAP net income of $3.04 million from a $44.25 million loss. Medical margin expanded to $73.66 million from $17.20 million, and management raised FY2026 adjusted EBITDA guidance to a $40 million midpoint. CEO Aric Coffman called the quarter “a meaningful turning point for the business.”

The bull case is straightforward: dramatic margin expansion, raised guidance, and a $252.5 million debt-to-preferred-equity conversion that resolves the NASDAQ compliance overhang. The risk that cuts the other way is real, including going concern doubt and negative stockholders’ equity of $143.5 million, plus an analyst target price of $3.50 that sits well below where shares closed. PIII is a high-conviction operational rerate that still has to prove its balance sheet.

Trio-Tech International (NYSE: TRT)

Trio-Tech International (NYSE:TRT) provides reliability testing services for semiconductor customers, with growing exposure to AI and EV chips. Shares closed at $20.05, up 43% on the session, putting the stock at the high end of its 52-week range of $2.31 to $21.38.

Fiscal Q3 2026 revenue hit $16.51 million, +123.6% YoY, with the Semiconductor Back-End Solutions segment up 141%. Trio-Tech also booked $7.8 million in cumulative Burn-In Board orders for a next-generation AI GPU platform and signed a lease on a 104,000 square foot facility in Penang, Malaysia. Market cap stands at $202.8 million.

The bull case is direct exposure to AI testing capacity at a triple-digit growth rate. The bear case is gross margin compression to 16% from 27%, the $10 million registered direct equity offering completed post-quarter, and trade-tension risk on Asia revenue. The trajectory looks like a small-cap AI infrastructure proxy with execution risk attached.

Super League Enterprise (NASDAQ: SLE)

Super League Enterprise (NASDAQ:SLE) sells in-game advertising on Roblox, Fortnite, Minecraft, and mobile. Shares closed at $6.04, up 48% on the day on 45.6 million shares. The market cap is tiny at roughly $9 million, which is why these moves get violent.

Q4 2025 EPS came in at -$0.96 versus a -$2.88 consensus, and the company ended 2025 debt-free with $14.39 million in cash, against $1.31 million the prior year. Management is guiding to cash-basis EBITDA profitability by year-end 2026 and gross margins toward 45%. CEO Matt Edelman said “Super League is a fundamentally different company than it was a year ago.” Wall Street’s target sits at $14.50.

Bull case: a debt-free, cash-funded turnaround with a pending Misfits Ads Division acquisition that represents roughly 50% of 2025 standalone revenue. Bear case: full-year 2025 revenue still declined 30%, the float is microscopic, and the acquisition needs stockholder approval. The setup rewards patience and conviction.

Do your own research, size positions accordingly, and treat single-day surges as a starting point for diligence rather than the conclusion of it.

Photo of Alex Sirois
About the Author Alex Sirois →

Alex Sirois is a financial writer with experience spanning both retail and institutional investing. He has written for InvestorPlace and held roles at BNY Mellon and Bernstein, giving him a perspective that bridges Main Street portfolios and Wall Street analysis.

Alex holds an MBA from George Washington University and has built his career across multiple industries, including e-commerce, education, and translation — a breadth of experience that informs how he breaks down complex financial topics for everyday investors. His writing is conversational, actionable, and grounded in long-term, buy-and-hold investing principles.

At 247 Wall St., Alex focuses on delivering analysis that is both accessible and useful, with a clear emphasis on helping readers make more informed decisions with their money.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

MRNA Vol: 14,456,655
FDS Vol: 1,547,130
NOW Vol: 27,314,826
WDAY Vol: 10,383,201
DDOG Vol: 9,628,007

Top Losing Stocks

ON Vol: 44,328,069
WDC Vol: 23,405,382
STX Vol: 9,311,397
KEYS Vol: 5,527,047
MPWR Vol: 3,481,726